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774Objectives: We aimed to analyze the accuracy of video-assisted mediastinoscopic lymphadenectomy
(VAMLA) as a tool for preoperative staging and the impact of the technique on survival in patients with
non–small cell lung cancer (NSCLC) undergoing pulmonary resection.
Methods: Between May 2006 and December 2010, 433 patients underwent pulmonary resection for NSCLC,
89 (21%) had VAMLA before resection and 344 (79%) had standard mediastinoscopy. The patients who had
negative VAMLA/mediastinoscopy results underwent anatomic pulmonary resection and systematic lymph
node dissection.
Results: The median and mean numbers of resected lymph node stations were 5 and 4.9 in the VAMLA group
and 4 and 4.2 in the mediastinoscopy group (P ¼ .9). The mean number of lymph nodes per biopsy specimen
using standard mediastinoscopy was 10.1, whereas it was 30.4 using VAMLA (P<.001). VAMLA unveiled N2
or N3 disease in 30 (33.7%) and in 6 (6.7%) of patients, respectively. The negative predictive value, sensitivity,
false-negative value, and accuracy of VAMLAwere statistically higher in the VAMLA groups compared with
those of standard mediastinoscopy. The 5-year survival was 90% for VAMLA patients and 66% for mediastino-
scopy patients (P ¼ .01). By multivariable analysis, VAMLA was associated with better survival (odds ratio,
1.34; 95% confidence interval, 1.1-3.2; P ¼ .02).
Conclusions: VAMLAwas associated with improved survival in NSCLC patients who had resectional surgery.
(J Thorac Cardiovasc Surg 2013;146:774-80)The best treatment for non–small cell lung cancer (NSCLC)
is dependent on correct staging of the disease. Nodal status
provides a pivotal role in anatomic staging of lung cancer.
Despite this fact, mediastinoscopy has been accepted as the
gold standard method for preoperative mediastinal staging
in patients with NSCLC, it has its inherent limitations, and
the false-negativity rate can be as high as 10% andwas equal
to the false-negativity rate of endobronchial ultrasound-
guided transbronchial needle aspiration.1 H€urtgen and col-
leagues2 developed a technique of radical video-assisted
mediastinoscopic lymphadenectomy (VAMLA).Theprimary
advantage of VAMLA over conventional mediastinoscopy or
videomediastinoscopy is to reduce the false-negative rate.2
However, the exact role of VAMLA has not been fully eluci-
dated. Our study aimed to assess the accuracy of regionale Departments of Thoracic Surgerya and Pathology,b Istanbul University,
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The Journal of Thoracic and Cardiovascular Surglymph node classification and its impact on survival for con-
ventional mediastinoscopy and video-assisted mediastino-
scopic lymphadenectomy.METHODS
Between May 2006 and December 2010, patients who had undergone
pulmonary resection for NSCLCwere analyzed. Mediastinal procedure se-
lection is purely based on the surgeon’s preference. All VAMLAprocedures
were performed by 1 surgeon (A.T.). However, mediastinoscopies in the
study were performed by experienced surgeons (A.D. and K.K.). One sur-
geon (A.T.) only performed VAMLA in all consecutive patients. Of all pa-
tients, 89 underwent VAMLA before operation, whereas 344 underwent
standard mediastinoscopic exploration. Two surgeons (A.D. and K.K.)
only performed standard mediastinoscopy. This is a retrospective cohort
study of prospectively recorded patients. The preoperativeworkup included
routine blood tests, posteroanterior and lateral chest radiographs, bronchos-
copy, pulmonary function tests, with or without diffusion capacity of lung
for carbon monoxide and ventilation-perfusion lung scan, and blood gas
analysis. Computed tomographic scans of the thorax, abdomen (or abdom-
inal ultrasonography), and cranium (or cranial magnetic resonance imag-
ing), and whole-body bone scintigraphy were performed in most patients
for pretreatment staging. Positron emission tomography–computed tomog-
raphy analysis was performed in a total of 401 patients. The patient charac-
teristics are shown in Table 1. There was no death or major complication
due to mediastinoscopy or VAMLA.
Mediastinal lymph node sampling through cervical mediastinoscopy at
stations 2, 4 (both left and right), and 7 was performed in almost all
patients. Preoperative mediastinal exploration was supplemented by left
anterior mediastinotomy (n ¼ 20) or extended mediastinoscopy (n ¼ 13)
in patients whose tumor lay in the left upper lobe or left main bronchusery c October 2013
TABLE 1. Patients’ clinical characteristics and distribution of clinical










Age (range), y 60.3 (20-81) 59.7 (44-79) >.05
Male/female ratio 290:54 70:19 >.05
Mean FVC (mL) 3210.5 3218.8 >.05
Mean FEV1 (mL) 2394.4 2298.9 >.05
Predicted FEV1,% 77.2 75.6
FEV1/FVC ratio 89.5 84.0 >.05
T stage, no. (%)
cT1a 43 (12.5) 15 (16.9)
cT1b 44 (12.8) 12 (13.5)
cT2a 118 (34.3) 32 (36.0)
cT2b 28 (8.1) 6 (6.7)
cT3 105 (30.5) 20 (22.5)
cT4 6 (1.7) 4 (4.5) >.05
VAMLA, Video-assisted mediastinoscopic lymphadenectomy; FVC, forced vital
capacity; FEV1, forced expiratory volume in 1 second.
Abbreviations and Acronyms
NSCLC ¼ non–small cell lung cancer
TEMLA ¼ transcervical extended mediastinal
lymphadenectomy
VAMLA ¼ video-assisted mediastinoscopic
lymphadenectomy
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Sand in those with enlarged anterior mediastinal or aorticopulmonary lymph
nodes (ie, stations 5 and 6). In our institution, mediastinoscopy (VAMLAor
standard mediastinoscopy) was performed routinely in patients with poten-
tially operable histologically proven NSCLC. In all, 433 (94.3%) of 459
patients underwent mediastinoscopy or VAMLA. We used a Linder-
Dahan videomediastinoscope (Richard Wolf, Knittlingen, Germany) for
VAMLA and a standard mediastinoscope (Richard Wolf) for standard
mediastinoscopy.
According to our institutional strategy, we did not operate on patients
with N2-N3 disease without oncological treatment (ie, radiotherapy and/
or chemotherapy) (Figure 1). Fifty patients who underwent VAMLA
(VAMLA-negative patients) and 279 patients who underwent standard me-
diastinoscopy were operated on. The type of resection was decided based
on anatomic tumor involvement. Pneumonectomy was performed in 88 pa-
tients (26.7%), sleeve lobectomy was performed in 14 patients (4.3%), bi-
lobectomy was performed in 51 patients (15.5%), wedge resection/
segmentectomy was done in 5 patients (1.5%), and (standard) lobectomy
was performed in 195 patients (59.3%). For pneumonectomy and lobec-
tomy, postoperative 30-day mortality rates were 6.8% (n ¼ 6) and 3.5%
(n ¼ 9), respectively. Complete resection was defined as the removal of
all detectable disease by the surgeon and histologic confirmation of
tumor-free resection margins. Complete resection was achieved in 307
cases (93.3%). The time between VAMLA/mediastinoscopy and pulmo-
nary resection was fewer than 30 days in almost all (97.6%) of patients
(319 of 327 patients who had pulmonary resection). Patients with tumor-
positive margins on final pathology review after complete gross resection
at thoracotomy were classified as having undergone incomplete resection
(n ¼ 22). A systematic mediastinal lymphadenectomy was performed in
every patient, in addition to anatomic lung resection (ie, all patients under-
went uniform staging to determine a final surgical-pathologic stage, based
on information obtained through thoracotomy and pathology examina-
tion).3 The final surgical-pathologic stage of the patients who underwent
resection before 2009 was reconstructed according to a recent staging sys-
tem.3 The CONSORT flow diagram of the study is shown in Figure 1.
Patients were grouped according to highest level of involved lymph
node station. The mean number of lymph nodes resected and examined
was 16 per patient (range, 2 to 67) for the N1 and N2 lymph node regions.
In the N1 region, a mean of 9 lymph nodes (range, 2 to 37) was removed.
All histologic specimens from patients were evaluated according to the
World Health Organization classification.4 Histopathologic tumor types
included squamous carcinoma in 210 cases (63.8%), adenocarcinoma in
89 cases (27.0%), and other non–small cell carcinoma types in 30 cases
(9.1%). An informed consent was obtained from every patient. The need
for Institutional Review Board Approval was waived according to our
country’s law because the study is a retrospective cohort study.
The distribution of clinical T factors is balanced in the VAMLA andme-
diastinoscopy groups, despite the fact that the rate of T4 tumors was higher
in patients who underwent VAMLA (P¼ .29) (Table 1). The surgical path-
ological T factors that were reconstructed using resected materials are also
balanced between 2 groups (Table 2).
Statistical Analysis
A c2 test was used for distribution of the T factor. A Mann-Whitney
U test was used for the comparison of biopsy specimen/resected lymphThe Journal of Thoracic and Canodes. The negative predictive value, sensitivity, and specificity were
calculated by the following formulas:
Negative Predictive Value ¼ [(Number of True Negatives)/(Number of
True Negatives þ Number of False Negatives)] 3 100
Sensitivity¼ [(Number of True Positives)/(Number of True Positivesþ
Number of False Negatives)] 3 100
Specificity¼ [(Number of True Negatives)/(Number of False Positivesþ
Number of True Negatives)]3 100
Accuracy¼ [(Number of True Negativesþ Number of True Positives)/
(Number of True Negatives þ Number of True Positives þ Number of
False Positives þ Number of False Negatives)] 3 100
Patient survival was expressed by analysis according to the Kaplan-
Meier method, using time 0 as the date of thoracotomy and death as the
end point. Perioperative deaths were included in survival analysis. We
performed an intention-to-treat analysis, including all patients who had un-
dergone resectional surgery during the study period. Prognostic factors
were evaluated in completely resected patients. Differences in survival
were determined using the log-rank test in the univariate analysis, and mul-
tivariate analysis was done using the Cox proportional hazards regression
model. The mean follow-up time was 20.1  20.1 months (range, 10 to
67 months). We also performed a propensity-matched analysis to compare
the patients in the VAMLA and standard mediastinoscopy groups.
Propensity matching was performed to identify 2 similar groups within
the standard mediastinoscopy and VAMLA groups. These groups were
matched with regard to age, sex, forced expiratory volume in 1 second,
and tumor histology clinical T stage. In this propensity analysis, 50
matched pairs were identified.RESULTS
Themedian number of resected lymph node station was 5
in the VAMLA group (mean, 4.9), whereas the median
number of station was 4 (mean, 4.1) in the mediastinoscopy
group (P ¼ .9). The mean number of lymph nodes per bi-
opsy specimen using standard mediastinoscopy was 10.1
(range, 2-33), whereas it was 30.4 (range, 18-110) using
VAMLA (P<.001). In the VAMLA group, lymph node dis-
section of stations 2R, 2L, 4R, 4L, 7, and 8 was achieved inrdiovascular Surgery c Volume 146, Number 4 775
FIGURE 1. CONSORT 2010 diagram of the study. VAMLA, Video-assisted mediastinoscopic lymphadenectomy.
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S85 (95.5%), 60 (67.4%), 86 (96.7%), 85 (95.6%), 88
(98.9%), and 23 (25.8%) of the patients, respectively. In
the standard mediastinoscopy group, 2R, 2L, 4R, 4L, 7,
and 8 underwent biopsy in 190 (55.2%), 89 (25.9%), 296
(86.0%), 189 (54.8%), 215 (62.5%), and 0 of the patients,
respectively. The difference was statistically significant
(P < .001). VAMLA statistically significantly disclosed
more disease (P<.001) (Table 3). The mean number of re-
sected mediastinal lymph nodes during pulmonary resec-
tion was 8.3 (range, 0-32) or 4.0 (range, 0-11) in patients
who underwent standard mediastinoscopy or VAMLA, re-
spectively (P<.001). Dysphonia was notified in 8 (9.0%)











pT1a 12 (24) 63 (22.5) >.05
pT1b 9 (18) 28 (10) >.05
pT2a 12 (24) 74 (27) >.05
pT2b 4 (8) 23 (8) >.05
pT3 11 (22) 88 (32) >.05
pT4 2 (4) 3 (1) >.05
Values are given as number (percentage). VAMLA, Video-assisted mediastinoscopic
lymphadenectomy.
776 The Journal of Thoracic and Cardiovascular Surgrate was 4.1% (13 dysphonia and 1 pneumothorax) in
patients who underwent standard mediastinoscopy. The dif-
ference was statistically significant (P ¼ .03). When com-
paring histopathologic staging from VAMLA with final
pathology, there were 3 false-negative (1 patient with sub-
carinal, 1 patient with 2R, and 1 patient with 8R metastasis)
results. In the standard mediastinoscopy group, 27 patients
(12, 3, 2, 2, 1, 2, and 1 patient with 7, 4, 2, 5, 6, 8R, and 9R
metastasis, respectively) had N2 disease after resection. The
negative predictive value, sensitivity, false-negative value,
and accuracy of VAMLA were statistically higher in
VAMLA groups compared with those of the standard me-
diastinoscopy group (Table 3). All (n ¼ 329) patients who
had undergone complete resectional surgery had a 5-year
survival of 66%, with a mean survival time of 50.6 months.
Kaplan-Meier estimation and log-rank comparison of the
survival data revealed that the 5-year survival rate of
patients who had VAMLA and subsequent pulmonary re-
section (n ¼ 50) was 90.0%, whereas it was 66.4% in pa-
tients who underwent mediastinoscopy and pulmonary
resection (n ¼ 279) (P ¼ .01) (Figure 2). N factor, T factor,
type of mediastinoscopy (VAMLA or standard mediastino-
scopy), sex, and type of operation were entered into the Cox
proportional (multivariate) analysis. Multivariate Cox anal-
ysis showed that performing VAMLA, absence of nodal me-
tastasis, and T factor were independently good prognostic
elements in resected patients (Table 4).ery c October 2013
TABLE 3. N stages of patients disclosed by mediastinal staging
modality (P< .001) and accuracy of mediastinal staging modalities









N0, no. (%) 288 (83.7) 53 (59.6) .023
N2-3, no. (%) 56 (16.2) 36 (40.4) <.001
Specificity 100.0 100.0 1
Sensitivity 67.5 95.5 .001
False-negative value 9.4 3.4 .04
Negative predictive value 90.6 94.3 .03
Accuracy 92.2 96.6 .04
Values are given as percentage, unless otherwise indicated. VAMLA, Video-assisted
mediastinoscopic lymphadenectomy.










Mediastinal metastasis (N2) 2.39 1.273-4.501 .007
T 1.43 1.004-2.055 .047
VAMLA vs standard mediastinoscopy 1.34 1.116-3.212 .02
VAMLA, Video-assisted mediastinoscopic lymphadenectomy.
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tify 2 similar groups within the standard mediastinoscopy
and VAMLA groups (n ¼ 50 in each group) (Tables 5 and
6). As shown in Figure 3, survival was significantly better
for the VAMLA groups: 86.5% at 5 years compared with
49.5% for the mediastinoscopy groups (P ¼ .002). Cox
regression confirmed that performing VAMLA provided in-
dependently better survival (Table 7).FIGURE 2. Survival curves of patients who underwent video-assistedme-
diastinoscopic lymphadenectomy (VAMLA) or standard mediastinoscopy.
The Journal of Thoracic and CaDISCUSSION
VAMLA is feasible and can be performed safely.2,4 Also,
the probability of false-negative mediastinoscopy results is
markedly decreased when more lymphoid tissue is resected
via VAMLA. Our results confirmed that more N2 and N3
disease was found by VAMLA. Thus, VAMLA prevented
more futile thoracotomies. These results were confirmed
with previous studies.2,4,5
More important, VAMLA led to a longer survival rate in
resected patients for NSCLC. Moreover, this impact of
VAMLA was independent of T or N factor. A propensity
analysis found that VAMLA provided better survival in
patients with resected NSCLC. To our knowledge, this sur-
vival benefit was not reported before. The possible reasons
for the survival benefit can be speculated: First, more accu-
rate preoperative invasive staging could have caused less
overlooked N2 disease; therefore, it could have helped us
to operate on real N0 patients. Particularly, the subcarinal
region can be completely dissected without suspicious
lymph node tissue left behind. In our study, standard media-
stinoscopy helped to disclose N2 disease in 16.2% of pa-
tients, whereas 40.4% of patients had N2 involvement,
despite the 2 groups being well balanced in terms of T fac-
tor. The effectiveness of VAMLAwas reported before.2,5 In
addition, we showed that VAMLA resulted in a higher
sensitivity and negative predictive value and a lower false-
negative rate. VAMLA provided a bilateral lymph node dis-
section before possible resectional surgery. This type of
lymph node dissection is nearly impossible during left tho-
racotomy because of great vessels. During right thoracot-
omy, bilateral dissection of lymph nodes is technically
challenging and time-consuming and usually necessitates
median sternotomy.6 The number of dissected lymph nodes
in patients who underwent VAMLAwas fewer than that of
those who had undergone standard mediastinoscopy
(P<.001) in our series. During VAMLA, paraesophageal
lymph nodes can be sampled, whereas lymph nodes adjacent
to pulmonary ligamentumcould not be reached. In our study,
number 8 lymph nodeswere sampled in 26% of patients.We
suggest that it is especially useful in patientswith right-sided
tumors who had an enlarged paraesophageal lymph node on
positron emission tomography–computed tomography or
computed tomography only. However, there are 2 technicalrdiovascular Surgery c Volume 146, Number 4 777
TABLE 5. Patient characteristics and preoperative T-stage distribution









Age (range), y 57.6 (20-81) 59.2 (45-82) >.05
Male/female ratio 47:3 45:5 >.05
Mean FVC 3079.3 3144.5 >.05
Mean FEV1 2342.5 2299.4 >.05
Predicted FEV1,% 76.1 75.3
FEV1/FVC ratio 92.7 82.3 .04
T stage, no. (%)
cT1a 9 (18.0) 8 (16.0)
cT1b 6 (12.0) 6 (12.0)
cT2a 16 (32.0) 19 (38.0)
cT2b 3 (6.0) 2 (4.0)
cT3 14 (28.0) 11 (22.0)
cT4 2 (4.0) 4 (8.0) >.05
VAMLA, Video-assisted mediastinoscopic lymphadenectomy; FVC, forced vital
capacity; FEV1, forced expiratory volume in 1 second.
FIGURE 3. Survival curves of propensity-matched non–small cell lung
cancer patients (n ¼ 50) who underwent either video-assisted mediastino-
scopic lymphadenectomy (VAMLA) or standard mediastinoscopy.
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Schallenges: First, before further dissection toward the para-
esophageal region, subcarinal lymph nodes must be com-
pletely dissected out and the right main pulmonary artery
should be mobilized. Second, a mediastinoscope should be
placed under the main pulmonary artery gently away from
the arterial branches. However, dissection of all paraesopha-
geal lymph nodeswas not technically possible. A longerme-
diastinoscope could have helped us to solve this technical
challenge.
The impact of radical lymphadenectomy was shown be-
fore.7 Ludwig and colleagues8 analyzed 16,800 patients and
reported that patient survival after resection for NSCLC is
associated with the number of lymph nodes evaluated dur-
ing surgery. Their data support the conclusion that an eval-
uation of nodal status should include more than 11 lymph
nodes. During VAMLA, we usually dissected more than
30 lymph nodes and our dissection could be somewhat
equal to lymph node dissection performed during thoracot-
omy or videothoracoscopy.TABLE 6. N stages of propensity-matched patients disclosed by
mediastinal staging modality (P<.001) and accuracy of mediastinal








N0, no. (%) 41 (82.0) 33 (66.0)
N2-3, no. (%) 9 (18.0) 17 (34.0)
Specificity 100 100
False-negative rate 100 5
Sensitivity 92 96
Values are given as percentage, unless otherwise indicated. VAMLA, Video-assisted
mediastinoscopic lymphadenectomy.
778 The Journal of Thoracic and Cardiovascular SurgThere are several advantages of VAMLA: VAMLA
seemed to disclose more N2 disease than was discovered
by standard mediastinoscopy. In our series, despite the 2
populations being balanced in terms of T factor, age, and
sex, more N2 disease was discovered by VAMLA. We also
have shown the effectiveness of VAMLA in propensity-
matched groups. The other advantage of VAMLA is that it
provides bilateral lymph node dissection before resectional
surgery and it theoretically diminishes ‘‘lymph node dissec-
tion time’’ during pulmonary resection, because lymph node
dissection, rather than lymph node biopsy, was performed
during the procedure. It should be especially important in
videothoracoscopic lobectomies. In our series, 5 thoraco-
scopic lobectomies were performed after VAMLA. During
dissection, we virtually dissect no lymph nodes or fatty tis-
sue at stations 2, 4, and 7 in these patients. For this reason,TABLE 7. Cox regression (multivariable) model for death hazard









Mediastinal metastasis (N2) 5.22 1.273-22.501 .003
T 1.21 0.911-4.593 .12
VAMLA vs standard mediastinoscopy 1.12 1.030-4.736 .04
VAMLA, Video-assisted mediastinoscopic lymphadenectomy.
ery c October 2013
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des in the VAMLA group is lower than that in the standard
mediastinoscopy group (P < .001). More important, 2L
and 4L lymph nodes can be completely dissected by
VAMLA, whereas they cannot be completely dissected after
video-assisted thoracic surgery lobectomy because it is tech-
nically demanding and it necessitates elevation of the aorta.
In our series, we also realized that VAMLA facilitates dis-
section of proximal arterial branches and bronchus during
video-assisted thoracic surgery and can reduce the operation
time while increasing the completeness of lymph node
dissection.
On the other hand, there are some disadvantages of
VAMLA: It takes more than 30 minutes, which is longer
than is necessary for standard mediastinoscopy . The longer
operation time was confirmed by Witte and colleagues.5 A
frozen section analysis of lymph nodes that were dissected
via VAMLA is time-consuming because the number of nec-
essary sections is too high. For this reason, we started to
send the specimen for standard histopathologic analysis in-
stead of sending lymph nodes to ‘‘frozen section’’ analysis.
The mean number of resected lymph nodes was 30.4 in the
VAMLA group. This number is higher than the mean num-
ber of resected lymph nodes during thoracotomy in most pa-
tients who underwent mediastinoscopy. Also, we performed
VAMLA in an outpatient setting. We also did not anticipate
hilar fibrosis during dissection in patients who had under-
gone the VAMLA procedure.
In a well-designed ACOSOG Z0030 study, Darling and
colleagues9 concluded that if systematic and thorough pre-
resection sampling of mediastinal and hilar lymph nodes is
negative, mediastinal lymph node dissection does not im-
prove survival in patients with stage I-II NSCLC.9 The re-
sults of this study should not be considered proof of lack
of the beneficial effect of lymph node dissection after surgi-
cal resection in patients with NSCLC because the patients
had early-stage lung cancer and all patients had already un-
dergone lymph node sampling.9
In 2004, Kuzdzal and colleagues10 developed the tech-
nique of limited invasive bilateral mediastinal lymph node
dissection, termed transcervical extended mediastinal lym-
phadenectomy (TEMLA). The TEMLA method enables
complete resection of all nodes from stations 2L, 2R, 3,
4R, 4L, 5, 6, 7, 8, and 9.10 It was an extremely accurate mo-
dality in NSCLC staging, with the additional advantage of
a potentially curative effect of the radical lymphadenec-
tomy.10 However, TEMLA is time-consuming and techni-
cally demanding, and there is a need for a special sternum
elevator. A study comparing these 2 lymph node dissection
and mediastinal staging techniques is warranted.
There are some limitations of the study that must be ad-
dressed. This study is a retrospective cohort study without
a randomization. Regarding the 2 surgeons’ preference of
standard mediastinoscopy, they believed that standardThe Journal of Thoracic and Camediastinoscopy was appropriate and is a straightforward
and quick method for preoperative mediastinal staging.
For this reason, these surgeons (A.D. and K.K.) and a sur-
geon performing VAMLA (A.T.) operated on consecutive
patients without any patient selection. There is also a possi-
bility that the results of VAMLA could be confounded with
a possible surgeon (A.T.)/skill effect that could not be sepa-
rated from VAMLA results. This possible effect could be
more understandablewhen considering that the number of re-
sected lymph nodes is greater than the number published.3,4
However, the optimal standards of mediastinoscopy or
VAMLA remain unknown. The complication rate of
VAMLAwas higher than that of mediastinoscopy. This may
be due to our higher rate of dissection of the 2L station.
This higher rate may also be due to our early experience of
VAMLA, in which the recurrent nerve was not identified
before commencing left-sided dissection. It is important to
start with identification of this nerve to reduce dysphonia.
In addition, electromyographic monitoring could have re-
duced the dysphonia rate if we had used it. Fortunately, all
but 1 case of dysphonia were resolved in 6 months. We
put all our efforts intodissecting the2L station in almost every
patient possible. This is probably one of the reasons that
dysphonia was higher in patients who underwent VAMLA.
During VAMLA, nodal tissue rarely is extracted completely
intact; instead, it comes out in fragments. For this reason, it
could be possible that some of the lymph nodes in our data
set were, in fact, fragments and the true number of lymph no-
des analyzed may have been overestimated. This phenome-
non is difficult to eliminate, and it was also mentioned to be
inevitable by Ludwig and colleagues.8
In conclusion, VAMLA seemed to provide better preop-
erative invasive staging, with higher sensitivity, negative
predictive value, and accuracy. It also independently pro-
longed survival in patients with operable NSCLC. Further
randomized studies with a longer follow-up are warranted
to confirm our results.References
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